ABL Bio Inc (298380)

Currency in KRW
74,600
+2,900(+4.04%)
Delayed Data·

298380 Financial Summary

Key Ratios

P/E Ratio-50.49
Price/Book26.04
Debt / Equity30.3%
Return on Equity-69.33%
Dividend Yield0.00%
EBITDA-56.97B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2021
31/12
2022
31/12
2023
31/12
2024
31/12
* In Millions of KRW (except for per share items)

Analyst Ratings

5 Buy
0 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 85,400
(+14.48% Upside)

Earnings

Latest Release
May 13, 2025
EPS / Forecast
-582.00 / -92.02
Revenue / Forecast
2.16B / --
EPS Revisions
Last 90 days

FAQ

What were ABL Bio's earnings for the latest quarter?

The ABL Bio EPS (TTM) is -1,489.50. ABL Bio reported sales of 2,164.69, net income of -28,148.23, and EPS of -582.00 for the latest quarter.

What was ABL Bio's net income for the latest quarter?

ABL Bio's net income for the latest quarter was -28,148.23.

How did ABL Bio's performance compare year-over-year in the latest quarter?

The company's revenue moved from 9,086.69 in the previous quarter to 2,164.69 in the latest quarter, and net income moved from -19,001.67 to -28,148.23 compared to the previous quarter.

What is ABL Bio's net profit margin on a TTM basis?

ABL Bio's trailing twelve months (TTM) net profit margin is -166.24%.

How does ABL Bio's debt to equity ratio compare to industry standards?

ABL Bio's total debt-to-equity ratio is 30.30%.

What is ABL Bio's return on investment on a TTM basis?

ABL Bio's trailing twelve months (TTM) return on investment (ROI) is -69.33%.

Did ABL Bio gain or lose cash last quarter?

In the latest quarter, ABL Bio's net change in cash was -33,061.00 million.

What were ABL Bio's total assets and liabilities in the latest quarter?

As of the latest quarter, ABL Bio reported total assets of 210,724.41 million and total liabilities of 66,079.47 million.

How has ABL Bio's total revenue grown this year?

ABL Bio's total revenue was 9,086.69 in the previous quarter and 2,164.69 in the latest quarter.

What is ABL Bio's gross margin on a TTM basis?

ABL Bio's trailing twelve months (TTM) gross margin is 99.81%.

What was ABL Bio's revenue per share for the latest quarter?

ABL Bio's revenue per share for the latest quarter was 1,019.86.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.